The majority of the available studies did not show any sign of harm associated with ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) in patients with COVID-19 (no significant association between the chronic use of RAS modifiers and either the risk to contract an infection or the risk of developing a severe or lethal form of the disease) [4,5]. Here, ACE is linked to COVID-19.